Barnaby Pickering

3 days ago | insights.citeline.com | Barnaby Pickering

In Conversation: “Decimated” FDA Teams Endanger Biologics Progress, Califf SaysIn Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit. Ex-FDA Comissioner Robert Califf • Source: Alamy

1 month ago | insights.citeline.com | Barnaby Pickering

Diagnostics Are Essential, But How Can Companies Ensure A Fair Price? Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?

Feb 4, 2025 | insights.citeline.com | Barnaby Pickering

As The Dust Settles, What Can We Learn From The J&J Vs. Auris Case? 04 Feb 2025 • By Barnaby PickeringIn September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.

Jan 17, 2025 | insights.citeline.com | Barnaby Pickering

Genetic Analysis Leaders On Gut Microbiota Testing, Pharma Connections And Direct-To-Consumer SceneGenetic Analysis CEO Ronny Hermansen and Christina Casén, senior VP of clinical and medical affairs, discuss the company’s polymerase chain reaction (PCR)-based approach to gut microbiota profiling versus DNA sequencing, competitive landscape, and opportunities for supporting pharma R&D and assessing drug treatment success.

Jan 2, 2025 | insights.citeline.com | Barnaby Pickering

When It Comes To Spine, Incumbents Are ‘Not Listening To Surgeons,’ Says Spineart CEO Jerome TrividicJerome Trividic, CEO of Swiss company Spineart, believes that by solving pain points felt by orthopedic surgeons performing spinal procedures, it can improve patient outcomes. He thinks the firm’s innovative approach, which focuses on partnership deals as well as developing its own products, will give it a competitive edge in the spinal surgery market.